1184 SYN101, a first in class, immune cell targeted TGF-beta inhibitor therapy, selectively blocks immune suppression and drives tumor clearance in vitro and in vivo | Zendy

AI Assistant Blog Pricing

1184 SYN101, a first in class, immune cell targeted TGF-beta inhibitor therapy, selectively blocks immune suppression and drives tumor clearance in vitro and in vivo

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.